The prognostic value of tumor mutational burden related 6-gene-based Risk Score in laryngeal cancer patients

BMC Oral Health. 2022 Nov 17;22(1):510. doi: 10.1186/s12903-022-02534-2.

Abstract

Background: Laryngeal cancer (LC) is the second frequent malignant head and neck cancer around world, while LC patients' prognosis is unsatisfactory. This study aims to investigate the prognostic value of tumor mutation burden (TMB)-related genes in LC.

Methods: LC data was downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. TMB values of all samples were calculated basing on mutation data. The differentially expressed genes (DEGs) between LC samples with distinct TMB were subjected to univariate and LASSO Cox regression analysis to build Risk Score. Immune cell infiltration analysis was conducted in CIBERSORT.

Results: Between high and low TMB LC samples, we identified 210 DEGs. Of which, six optimal genes were included to construct Risk Score, comprising FOXJ1, EPO, FGF5, SPOCK1, KCNF1 and PSG5. High risk LC patients had significantly poorer overall survival than low risk patients. The nomogram model constructed basing on Risk Score and gender showed good performance in predicting LC patients' survival probability.

Conclusions: The prognostic Risk Score model, basing on six TMB-related genes (FOXJ1, EPO, FGF5, SPOCK1, KCNF1 and PSG5), was a reliable prognostic model to separate LC patients with different prognoses.

Keywords: Laryngeal cancer (LC); Nomogram model; Risk Score; Tumor mutation burden (TMB).

MeSH terms

  • Biomarkers, Tumor / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Laryngeal Neoplasms* / genetics
  • Prognosis
  • Proteoglycans
  • Risk Factors

Substances

  • Biomarkers, Tumor
  • SPOCK1 protein, human
  • Proteoglycans